In gastric cancer patients, CD133 is expressed in more than 50% of the cases, and its expression appears as an independent prognostic marker for poor patient prognosis, high CD133 is associated with poor patient survival rates [40]. The gene discussed is PROM1; the disease is gastric cancer.